Clinical Trial Update: Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing ADI-PEG 20 to placebo in advanced hepatocellular carcinoma after prior systemic therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Polaris Group | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED